Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
REGN or INCY: Which Is the Better Value Stock Right Now?
12:41pm, Wednesday, 05'th Aug 2026
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Regeneron (REGN) or Incyte (INCY). But which of these two stocks is more attractive to value
New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
10:01am, Sunday, 02'nd Aug 2026
Minjuvi (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy
Here's Why Incyte (INCY) is a Strong Momentum Stock
10:51am, Thursday, 30'th Jul 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Incyte (INCY) is a Strong Growth Stock
10:46am, Wednesday, 29'th Jul 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the EU for Adults with Moderate Atopic Dermatitis.
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
01:40pm, Tuesday, 28'th Jul 2026
Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.
Incyte Corporation (INCY) Q2 2026 Earnings Call Transcript
12:23pm, Tuesday, 28'th Jul 2026
Incyte Corporation (INCY) Q2 2026 Earnings Call Transcript
Here's Why Incyte (INCY) is a Strong Value Stock
10:41am, Tuesday, 28'th Jul 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics
10:31am, Tuesday, 28'th Jul 2026
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to
Incyte Q2 Earnings Call Highlights
10:05am, Tuesday, 28'th Jul 2026
Incyte NASDAQ: INCY reported second-quarter 2026 net product sales of $1.49 billion, up 40% from a year earlier, supported by demand growth across its marketed portfolio and a one-time non-cash benefi
Incyte: From Buy To Hold After A 93% Rally (Rating Downgrade)
09:33am, Tuesday, 28'th Jul 2026
Incyte Corporation ends the first half of 2026 on a high note. Yesterday, its stock reached a 52-week high of $120.70. In my view, key drivers behind Incyte's recent rally are the promising efficacy o
Incyte (INCY) Q2 Earnings and Revenues Top Estimates
09:16am, Tuesday, 28'th Jul 2026
Incyte (INCY) came out with quarterly earnings of $3.09 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $1.57 per share a year ago.
Incyte lifts annual revenue forecast after settlement with CMS
09:00am, Tuesday, 28'th Jul 2026
Drugmaker Incyte Corp reported on Tuesday higher second-quarter earnings and raised its annual revenue forecast after it settled a lawsuit with the U.S. government over Medicaid rebates tied to
ServiceNow, Meta, eBay And A Health Care Stock On CNBC's ‘Final Trades'
08:18am, Tuesday, 28'th Jul 2026
On CNBC's “Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, picked ServiceNow, Inc. (NYSE:NOW).
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
07:00am, Tuesday, 28'th Jul 2026
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates.
